CAJ | 학술논문

目的：观察吉非替尼治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应，并探讨相关护理方案。方法选取晚期 NSCLC 患者110例，给予吉非替尼250 mg ／d 治疗。评价近期疗效，观察不良反应并总结相关护理工作。结果客观缓解率为14．5％，疾病控制率为59．1％。主要不良反应为皮疹54例，腹泻32例，恶心呕吐14例，转氨酶升高13例，无患者因不耐受而停药。结论吉非替尼能够一定程度缓解 NSCLC 进展，用药期间要针对不良反应加强护理。
목적：관찰길비체니치료만기비소세포폐암（NSCLC）적림상료효급불량반응，병탐토상관호리방안。방법선취만기 NSCLC 환자110례，급여길비체니250 mg ／d 치료。평개근기료효，관찰불량반응병총결상관호리공작。결과객관완해솔위14．5％，질병공제솔위59．1％。주요불량반응위피진54례，복사32례，악심구토14례，전안매승고13례，무환자인불내수이정약。결론길비체니능구일정정도완해 NSCLC 진전，용약기간요침대불량반응가강호리。
ABSTRACT:Objective To observe the clinical effects of and side reaction to gefitnib in treat-ment of non-small cell lung cancer (NSCLC),and to discuss related nursing interventions.Meth-ods A total of 110 NSCLC patients were administrated with gefitinib 250 mg per day.Response rate and side effects were observed regularly,and nursing experience was summarized after treat-ment.Results Overall response rate and disease control rate was 14.5% and 59%,respectively. Out of 110 patients,54 with skin rash,32 with diarrhea,14 with nausea and 13 with increased aminotransferase,but were reversible by nursing care.Conclusion Gefitnib shows effects in treat-ing NSCLC,and intensive nursing care is required to prevent side reactions.